Introduction
Aromatic heterocycles are present in numerous molecules of chemical or biological interest, as well as in organic materials for different applications. In particular, N-(pyridyl) azoles are key skeletons present in pharmaceuticals 1 and in functional materials.
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The development of simple methods to build such scaffolds is thus of interest. Among them, deprotonative 3 and dehalogenative 4 metalations, using respectively polar organometallic bases and transition metal catalysts, are powerful tools.
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We here report our efforts to combine deprotometalation-iodolysis of methoxypyridines with Narylation of azoles for the synthesis of pyridine-based C,N'-linked bis-heterocycles. The antiproliferative activation of the obtained scaffolds in melanoma cells has also been evaluated.
Results and Discussion
We recently developed a deprotometalation-iodolysis-N-arylation sequence from benzothiophene, benzofuran, benzothiazole and benzoxazole to access various bis-heterocycles. 11 In this study, deprotolithiation followed by in situ trans-metal trapping of the five-membered aromatic heterocycles was carried out in THF (THF = tetrahydrofuran) before iodolysis by using a basic combination prepared from ZnCl 2 ·TMEDA and LiTMP in a 1:3 ratio, [8] [9] 12 and supposed to afford 1:1 Zn(TMP) 2 -LiTMP·2LiCl±TMEDA. [7] [8] The crude iodides were directly involved in the N-arylation of different azoles (1.5 equiv) in the presence of metal copper (0.2 equiv), cesium carbonate (2 equiv) and acetonitrile, at the reflux temperature of the solvent for 24 h. 13 In order to reach N-pyridyl azoles, we applied this procedure to the commercially available methoxypyridines 1a, 2a and 3a (Table 1) . From 2-methoxypyridine (1a), the expected N-(2-methoxy-3-pyridyl) azoles were isolated in the case of pyrrole (product 1b, entry 1), pyrazole (1c, entry 2) and benzimidazole (1d, entry 3). The low yields are, at least to some extent, due to the insufficient amount of lithium-zinc base used; indeed, 2-methoxypyridine (1a) is much more completely deprotometalated by employing 1 equiv of ZnCl 2 ·TMEDA and 3 equiv of LiTMP. 9b The N-arylation of benzimidazole (product 1d) appears as less efficient, when compared with those of pyrrole and pyrazole.
We previously showed that 3-methoxypyridine (2a) can be deprotonated upon treatment by the lithium-zinc base, in situ prepared from 0.5 equiv of ZnCl 2 ·TMEDA and 1.5 equiv of LiTMP, in THF at 20 °C for 2 h. The regioselectivity of the reaction is however incomplete; indeed, subsequent quenching with iodine afforded the 4-iodo derivative 2a-I in 85% yield together with 10% of the 2-iodo derivative 2a-I'. 9b Therefore, if the isolation of the N-(3-methoxy-2-pyridyl) analogues 2b', 2e', 2d'
and 2f' after reacting the crude coming from deprotometalation-iodolysis with pyrrole (entry 4), indole
(entry 5), benzimidazole (entry 6) and indazole (entry 7) is not surprising, the absence of N-(3-methoxy-4-pyridyl) azoles 2b, 2e, 2d and 2f is unexpected.
Similarly, whereas 4-methoxypyridine (3a) led to 3-iodo-4-methoxypyridine (3a-I) in 89% yield after deprotometalation-trapping under the conditions here used, the expected N- (4-methoxy-3-pyridyl) azoles 3b, 3c, 3f and 3g were not identified. Instead, the corresponding N-(4-methoxy-2-pyridyl) azoles 3b', 3c', 3f' and 3g' were isolated in low yields (entries [8] [9] [10] [11] .
The N-(3-methoxy-2-pyridyl) analogues 2b', 2e', 2d', 2f' and N-(4-methoxy-2-pyridyl) azoles 3b', 3c', 3f', 3g' could be formed by azole N-arylation with 2-iodo-3-methoxypyridine (2a-I') and 2-iodo-4-methoxypyridine (3a-I'), respectively. Such 2-iodo derivatives 2a-I' and 3a-I' can be generated in the course of the deprotometalation-iodolysis reaction. Alternatively, iodine stored by reaction with LiTMP in the course of the iodolysis 14 could work as an oxidant in the coupling step, allowing a crossdehydrogenative C-N bond formation to occur. 15 In these reactions, a part of the 3-iodo intermediate 1a-I (entries 1-3), and all the 4-iodo compound 2a-I (entries 4-7) or 3-iodo compound 3a-I (entries 8-11) are not converted by N-arylation under the conditions employed. Table 1 . Deprotometalation-iodolysis of the methoxypyridines 1a, 2a and 3a followed by N-arylation of azoles with the crude iodides 1a-I, 2a-I and 3a-I. a After purification by column chromatography. b 2-Methoxypyridine (1a, due to incomplete deprotometalation) and 3-iodo-2-methoxypyridine (1a-I) were also recovered.
c 4-Iodo-3-methoxypyridine (2a-I) and some 3-methoxypyridine (2a) were also recovered, and degradation was noticed. d 3-Iodo-4-methoxypyridine (3a-I) and some 4-methoxypyridine (3a) were also recovered.
This preliminary study led us to next compare different N-arylation procedures to generate N-(4-methoxy-3-pyridyl)pyrrole (3b), starting from purified 3-iodo-4-methoxypyridine (3a-I) and pyrrole (Table 2) . First, the protocol using copper and cesium carbonate (2 equiv) at acetonitrile reflux for 24 h was applied; 13 no reaction was observed with either 0.2 or 0.4 equiv of transition metal (entries 1 and 2), in accordance with the results obtained in Table 1 (entries [8] [9] [10] [11] . It is interesting to notice that N-(4-methoxy-2-pyridyl) pyrrole (3b') was not obtained either, allowing to discard both direct addition of copper azolates onto pyridines and conversion of 3a-I into 3a-I' by halogen loss followed by halogenation 16 at a different site. with 3-iodopyridine, 12g allowed 3b to be isolated in about 40% yield (entries 6 and 7). The yield dropped to 13% by increasing the amount of TMEDA to 1 equiv (entry 8).
Because azoles can be N-arylated with iodopyridines in the presence of copper(I) oxide (0.1 equiv), cesium carbonate (2 equiv) and DMSO (DMSO = dimethylsulfoxide) at 110 °C, 20 we also evaluated this protocol. After 24 h reaction with 1 equiv of pyrrole, 3b was isolated in 45% yield (entry 9).
Doubling the amount of azole furnished 3b in a slightly higher 55% yield (entry 10). Table 2 . N-arylation of pyrrole with purified 3-iodo-4-methoxypyridine (3a-I).
Cu source (n equiv) Base (2 equiv) Ligand (n' equiv) (Table 3) . By using potassium triphosphate as base and TMEDA as ligand (0.1 equiv) with copper(I) iodide (0.05 equiv) in DMF at 110 °C (protocol A), 19 the expected N-pyridyl pyrroles 1b-5b
were isolated in moderate yields, varying between 25% in the case of 3-iodo-2,6-dimethoxypyridine (5a-I, entry 17) and 54% for 3-iodo-2-methoxypyridine (1a-I, entry 1).
Turning to protocol B, with cesium carbonate as base and copper(I) oxide (0.1 equiv) in DMSO at 110 °C, led to the same derivatives 1b-5b in improved yields. Competitive substitution of the methoxy group at the 4 position was noticed from 3a-I under these conditions, allowing the bis-pyrrole 3b" to be also isolated in 7% yield (entry 10). Upon similar treatment, 4-methoxypyridine (3a) was converted to N-(4-pyrridyl)pyrrole in 5% yield. 21 By replacing pyrrole by indole or benzimidazole, the best conditions (protocol B) were employed in order to synthesize the corresponding N-pyridyl indoles 1e-5e and N-pyridyl benzimidazoles 1d-5d (Table 3) . When compared with those recorded with pyrrole (products 1b-5b), lower yields were noticed with indole (products 1e-5e) and, above all, with benzimidazole (products 1d and 2d; 3d-5d not obtained).
The formation of the N-(4-methoxy-3-pyridyl) azoles 3e and 3d suffered from important competitive generation of N-methyl-indole and -benzimidazole, probably formed with cleavage of the methoxy group (entries 11 and 12). Lithium iodide-mediated cleavage of aryl methyl ethers is known, 22 but this salt is not present in this reaction performed on purified 3a-I; the side reaction could rather take place between the N-metalated azoles and the ether function. Moreover, 4-methoxypyridines are more prone to cleavage than their 2-and 3-methoxylated isomers, 23 a reason explaining why this side reaction more importantly takes place from 3a-I.
Only one benzimidazole N-arylation by an iodinated methoxypyridine is reported, between 3-iodo-2-methoxypyridine (1a-I) and 4-(4-methyl-3-pyridyl)benzimidazole under conditions similar to those of protocol A. 24 Besides its possible N-methylation, benzimidazole can lead to other side reactions.
Indeed, after N-functionalization (by methylation or arylation), it is possible to make the second nitrogen react in turn by N-methylation 25 or even N-pyridylation. 26 In addition, once demethylated, the resulting pyridinones can also compete with benzimidazole in arylation reactions. Such possibilities could in our case furnish many unwanted products (degradation) under the harsh conditions employed, in particular in the case of the iodo substrates less prone to undergo N-arylation reaction. Table 3 . N-arylation of azoles with the purified iodides 1a-I, 2a-I, 3a-I, 4a-I and 5a-I. a After purification by column chromatography. b Prepared in 98% yield as described previously.
9b c 3-Iodo-2-methoxypyridine (1a-I) and some 2-methoxypyridine (1a) were also recovered.
d Prepared in 85% yield as described previously. 9b e 4-Iodo-3-methoxypyridine (2a-I) and some 3-methoxypyridine (2a) were also recovered, and degradation was noticed.
f Prepared in 89% yield as described previously.
9b g 3-Iodo-4-methoxypyridine (3a-I) and some 4-methoxypyridine (3a) were also recovered.
h 3,4-Bis(1-pyrrolyl)pyridine (3b") was also isolated in 7% yield. i N-methyl indole was also obtained in 66% yield.
j N-methyl imidazole was also obtained in 40% yield.
k Prepared in 98% yield as described previously. 9b l 4-Iodo-2,3-dimethoxypyridine (4a-I) and some 2,3-dimethoxypyridine (4a) were (also) recovered.
m Prepared in 98% yield as described previously.
9b n 3-Iodo-2,6-dimethoxypyridine (5a-I) and some 2,6-dimethoxypyridine (5a) were (also) recovered.
Figure 1. ORTEP diagrams (30% probability) of 1d, 1e, 2b, 2e and 5b.
The compounds 1d, 1e, 2b, 2e and 5b were identified unambiguously by X-ray diffraction (Figure 1 ).
We tried to roughly rationalize the results obtained from these N-arylations. One can predict that the reactivities of 1a-I, 2a-I, 3a-I, 4a-I and 5a-I are related to the partial positive charge on the carbon bearing iodine, as it is for nucleophilic substitution. Handy and Zhang showed that this positive charge can be accounted for by the corresponding 1 H NMR chemical shift of the respective deiodinated substrates 1a, 2a, 3a, 4a and 5a (Table 4) . Finally, by using pyrrole as azole, the protocols A and B were compared for their ability to achieve the deprotometalation-iodolysis-N-arylation sequence of the methoxypyridines 1a-5a (Table 5) . To this purpose, the recently optimized 9b deprotometalation-iodolysis conditions were employed. To reach the M A N U S C R I P T
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11 N-pyridyl pyrroles 1b-5b, protocol B proved to be a procedure superior to protocol A, furnishing the expected derivatives in yields ranging from 45 to 90%. Table 5 . Deprotometalation-iodolysis of the methoxypyridines 1a, 2a, 3a, 4a and 5a followed by Narylation of pyrrole with the crude iodides 1a-I, 2a-I, 3a-I, 4a-I and 5a-I. a After purification by column chromatography. b 3-Iodo-2-methoxypyridine (1a-I) and some 2-methoxypyridine (1a) were also recovered.
c The isomer 2b' was also isolated in 11% yield. 4-Iodo-3-methoxypyridine (2a-I) and some 3-methoxypyridine (2a) were also recovered, and degradation was noticed. d The isomer 3b' was also isolated in 6% yield. 3-Iodo-4-methoxypyridine (3a-I) and some 4-methoxypyridine (3a) were also recovered, and degradation was noticed.
e 4-Iodo-2,3-dimethoxypyridine (4a-I) and some 2,3-dimethoxypyridine (4a) were also recovered.
f 3-Iodo-2,6-dimethoxypyridine (5a-I) and some 2,6-dimethoxypyridine (5a) were also recovered. casein kinase 1 (CK1) and Haspin. None of the compounds described in this article were shown to inhibit significantly the tested kinases (residual activity was above 50% when the kinase is treated with 10 -5 M of compound, data not shown). The protocol used is as described previously.
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Figure 2: Antiproliferative activity of the compounds 1-5e, 1b and 5b at 10 -5 M and 72 h in A2058 human melanoma cells.
Conclusion
Thus, after preliminary optimization of separate deprotometalation-iodolysis and N-arylation steps, it was found possible to combine both reactions in a sequence (either protocol A using CuI, TMEDA, M A N U S C R I P T A C C E P T E D Bruker-AXS diffractometer (compounds 1d, 1e, 2e and 5b) or D8 VENTURE Bruker AXS diffractometer (compound 2b). The structure was solved by direct methods using the SIR97 program, 30 and then refined with full-matrix least-square methods based on F 2 (SHELX-97) 31 with the aid of the WINGX program. 32 All non-hydrogen atoms were refined with anisotropic atomic displacement parameters. H atoms were finally included in their calculated positions. Molecular diagrams were generated by ORTEP-3 (version 2.02). 
General procedure 1
To a stirred, cooled (0 °C) solution of 2,2,6,6-tetramethylpiperidine (0.25 mL, 1.5 mmol) in THF (2-3 mL) were successively added BuLi (about 1.6 M hexanes solution, 1.5 mmol) and, 5 min later, washing with AcOEt, removal of the solvent and purification by chromatography on silica gel (the eluent is given in the product description) led to the compound described below. 
2-Methoxy-3-(1-pyrazolyl)pyridine (1c
3-Methoxy-2-(1-pyrryl)pyridine (2b').
The general procedure 1 using 3-methoxypyridine (2a, 0.11 mL) and pyrrole (0.10 mL) gave 2b' (eluent: heptane-AcOEt 20:80) in 42% yield as a yellow oil: 
2-(1-Indolyl)-3-methoxypyridine (2e').
The general procedure 1 using 3-methoxypyridine (2a, 0.11 mL) and indole (0.12 g) gave 2e' (eluent: heptane-AcOEt 20:80) in 39% yield as a yellow oil: IR 
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2-(1-Benzimidazolyl)-3-methoxypyridine (2d').
2-(1-Indazolyl)-3-methoxypyridine (2f'
)
4-Methoxy-2-(1-pyrryl)pyridine (3b'
2-(1-Indazolyl)-4-methoxypyridine (3f').
2-(1-Benzotriazolyl)-4-methoxypyridine (3g'
General procedure 2
A mixture of the required iodide (1.0 mmol), Cu 2 O (0.10 g, 0.10 mmol), Cs 2 CO 3 (0.65 g, 2.0 mmol), the required azole (2.0 mmol) and DMSO (0.5 mL) was stirred for 24 h at 110 °C. After cooling to room temperature, the mixture was diluted with AcOEt (10 mL) and filtered over celite ® . Washing with AcOEt, removal of the solvent and purification by chromatography on silica gel (the eluent is given in the product description) led to the compound described below.
2-Methoxy-3-(1-pyrryl)pyridine (1b).
The general procedure 2 using 3-iodo-2-methoxypyridine 
3-(1-Indolyl)-2-methoxypyridine (1e).
3-Methoxy-4-(1-pyrryl)pyridine (2b)
.
4-Methoxy-3-(1-pyrryl)pyridine (3b).
The general procedure 2 using 3-iodo-4-methoxypyridine CCDC 1484505. 
4-(1-Indolyl)-2,3-dimethoxypyridine (4e)
2,6-Dimethoxy-3-(1-indolyl)pyridine (5e)
Biological evaluation
The antiproliferative activity of N-pyridyl azoles was studied in the A2058 (ATCC® CRL 
